BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33249415)

  • 1. Is the Oncological Outcome of Early Stage Uterine Carcinosarcoma Different from That of Grade 3 Endometrioid Adenocarcinoma?
    Güngördük K; Plett H; Gülseren V; Meydanlı M; Boyraz G; Özdemir İ; Şahin H; Şenol T; Yıldırım N; Turan T; Öge T; Gökçü M; Taşkın S; Ayhan A; Ataseven B
    Oncol Res Treat; 2021; 44(1-2):43-51. PubMed ID: 33249415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
    Zhu J; Wen H; Bi R; Wu X
    J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic characteristics and prognosis comparison of the uterine high grade endometrial carcinomas.
    Sucu M; Kucukgoz Gulec U; Paydas S; Guzel AB; Kilic Bagir E; Vardar MA
    Ginekol Pol; 2021; 92(4):278-283. PubMed ID: 33751504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of survival outcomes and effects of therapy between subtypes of high-grade endometrial cancer - a population-based study.
    Scharl S; Gerken M; Sprötge T; Kronberger K; Scharl A; Ignatov A; Ortmann O; Kölbl O; Klinkhammer-Schalke M; Papathemelis T
    Acta Oncol; 2021 Jul; 60(7):897-903. PubMed ID: 33905297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.
    Mhawech-Fauceglia P; Wang D; Kesterson J; Syriac S; Clark K; Frederick PJ; Lele S; Liu S
    PLoS One; 2011 Mar; 6(3):e18066. PubMed ID: 21448288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes of women with grade 3 endometrioid endometrial cancer: the impact of adjuvant treatment strategies.
    Gungorduk K; Muallem J; Aşıcıoğlu O; Gülseren V; Güleç ÜK; Meydanlı MM; Sehouli J; Özdemir A; Şahin H; Khatib G; Miranda A; Boran N; Şenol T; Yıldırım N; Turan T; Oge T; Taşkın S; Vardar MA; Ayhan A; Muallem MZ
    Arch Gynecol Obstet; 2022 Mar; 305(3):671-681. PubMed ID: 34448946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
    Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
    Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence patterns and prognostic factors in lymphovascular space invasion-positive endometrioid endometrial cancer surgically confined to the uterus.
    Sahin H; Meydanli MM; Sari ME; Kocaman E; Cuylan ZF; Yalcin I; Coban G; Özen Ö; Sirvan L; Güngör T; Ayhan A
    Taiwan J Obstet Gynecol; 2019 Jan; 58(1):82-89. PubMed ID: 30638487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.
    Fader AN; Java J; Tenney M; Ricci S; Gunderson CC; Temkin SM; Spirtos N; Kushnir CL; Pearl ML; Zivanovic O; Tewari KS; O'Malley D; Hartenbach EM; Hamilton CA; Gould NS; Mannel RS; Rodgers W; Walker JL
    Gynecol Oncol; 2016 Dec; 143(3):460-465. PubMed ID: 27743738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and multiparametric MRI features for differentiating uterine carcinosarcoma from endometrioid adenocarcinoma.
    Chen X; Guo Q; Chen X; Zheng W; Kang Y; Cao D
    BMC Med Imaging; 2024 Feb; 24(1):48. PubMed ID: 38373912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
    Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; McKee B; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):79-85. PubMed ID: 12182977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
    Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
    Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
    McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
    Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma.
    Sozen H; Çiftçi R; Vatansever D; Topuz S; Iyibozkurt AC; Bozbey HU; Yaşa C; Çali H; Yavuz E; Kucucuk S; Aydiner A; Salihoglu Y
    Aust N Z J Obstet Gynaecol; 2016 Apr; 56(2):199-206. PubMed ID: 26890292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival.
    Raffone A; Travaglino A; Raimondo D; Maletta M; De Vivo V; Visiello U; Casadio P; Seracchioli R; Zullo F; Insabato L; Mollo A
    Int J Gynaecol Obstet; 2022 Sep; 158(3):520-527. PubMed ID: 34797919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
    Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
    [No Abstract]   [Full Text] [Related]  

  • 17. Does the Increased Rate of Serous Component (≤25% vs. >25%) Increase Recurrence in Endometrial Cancer With Serous Plus Endometrioid Histology?
    Kaban A; Topuz S; Sozen H; Salihoglu Y
    J Obstet Gynaecol Can; 2019 Feb; 41(2):160-165. PubMed ID: 30316715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the extent of lymphadenectomy a prognostic factor in International Federation of Gynecology and Obstetrics stage II endometrioid endometrial cancer?
    Cuylan ZF; Akilli H; Gungorduk K; Demirkiran F; Oz M; Salman MC; Sozen H; Celik H; Gokcu M; Bese T; Meydanli MM; Ozgul N; Topuz S; Kuscu E; Kuru O; Gokmen S; Gultekin M; Ayhan A
    J Obstet Gynaecol Res; 2021 Mar; 47(3):1134-1144. PubMed ID: 33426779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
    Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
    Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
    Xu MJ; Chu C; Rubin S; Lin LL
    Am J Clin Oncol; 2017 Dec; 40(6):598-604. PubMed ID: 26237194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.